Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma (Q40177381)

18 September 2017

Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma (English)

1 reference

18 September 2017

1 reference

11

Edward A Neuwelt

1 reference

18 September 2017

Nancy D Doolittle

1

1 reference

18 September 2017

Kristoph Jahnke

2

1 reference

18 September 2017

Richard Belanger

3

1 reference

18 September 2017

Deborah A Ryan

4

1 reference

18 September 2017

Robert W Nance

5

1 reference

18 September 2017

Cynthia A Lacy

6

1 reference

18 September 2017

Rose Marie Tyson

7

1 reference

18 September 2017

Marianne Haluska

8

1 reference

18 September 2017

Nancy A Hedrick

9

1 reference

18 September 2017

Csanad Varallyay

10

1 reference

18 September 2017

1 September 2007

1 reference

18 September 2017

1 reference

18 September 2017

48

1 reference

18 September 2017

9

1 reference

18 September 2017

1712-1720

1 reference

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

18 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Primary CNS lymphoma: a whole-brain disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Prospective trial on topotecan salvage therapy in primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Current status and future of relapsed primary central nervous system lymphoma (PCNSL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493902

10.1080/10428190701493902

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference